Genentech Reports the US FDA Acceptance of sBLA for Polivy (polatuzumab vedotin-piiq) to Treat Diffuse Large B-Cell Lymphoma
- The sBLA was based on the P-III (POLARIX) trial that evaluates Polivy + R-CHP vs R-CHOP in 879 patients in a ratio (1:1) with DLBCL. The US FDA’s decision on approval is expected on April 2, 2023
- The results showed an improvement in PFS, 27% reduction in risk of disease progression, relapse, or death after a median follow-up of 28.2mos. The safety outcomes were consistent with prior trials, grade 3-4 AEs (57.7% vs 57.5%), SAEs (34.0% vs 30.6%), grade 5 AEs (3.0% vs 2.3%), and AEs leading to dose reduction (9.2% vs 13.0%)
- The therapy is currently approved as a readily available, fixed-duration treatment option for r/r DLBCL in combination with bendamustine and Rituxan/Mabthera in 70+ countries globally incl in the US & EU
Ref: GlobeNewswire | Image: Genentech
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.